Oral vitamin B12 supplement is delivered to the distal gut, altering the corrinoid profile and selectively depleting Bacteroides in C57BL/6 mice
| Autor: | Campbell Eric L, Daniel N. Frank, Kayla D. Battista, Thad W. Vickery, David Kitzenberg, Linda Farb, Caleb J. Kelly, Charles E. Robertson, Sean P. Colgan, Leon Zheng, Sally P. Stabler, Douglas J. Kominsky, Erica E. Alexeev |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
0301 basic medicine
Microbiology (medical) C57BL/6 Administration Oral Pharmacology Microbiology Inflammatory bowel disease Feces 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Corrinoid polycyclic compounds medicine Animals Bacteroides Vitamin B12 Colitis Cecum biology Brief Report Dextran Sulfate Gastroenterology nutritional and metabolic diseases Fatty Acids Volatile medicine.disease biology.organism_classification Gastrointestinal Microbiome Mice Inbred C57BL Vitamin B 12 stomatognathic diseases 030104 developmental biology Infectious Diseases chemistry Dietary Supplements Vitamin B Complex Oral vitamin Corrinoids 030211 gastroenterology & hepatology |
| Zdroj: | Gut Microbes |
| ISSN: | 1949-0984 1949-0976 |
| DOI: | 10.1080/19490976.2019.1597667 |
| Popis: | Vitamin B(12) is a critical nutrient for humans as well as microbes. Due to saturable uptake, high dose oral B(12) supplements are largely unabsorbed and reach the distal gut where they are available to interact with the microbiota. The aim of this study was to determine if oral B(12) supplementation in mice alters 1) the concentration of B(12) and related corrinoids in the distal gut, 2) the fecal microbiome, 3) short chain fatty acids (SCFA), and 4) susceptibility to experimental colitis. C57BL/6 mice (up to 24 animals/group) were supplemented with oral 3.94 µg/ml cyanocobalamin (B(12)), a dose selected to approximate a single 5 mg supplement for a human. Active vitamin B(12) (cobalamin), and four B(12)-analogues ([ADE]CN-Cba, [2Me-ADE]CN-Cba, [2MeS-ADE]CN-Cba, CN-Cbi) were analyzed in cecal and fecal contents using liquid chromatography/mass spectrometry (LC/MS), in parallel with evaluation of fecal microbiota, cecal SCFA, and susceptibility to dextran sodium sulfate (DSS) colitis. At baseline, active B(12) was a minor constituent of overall cecal (0.86%) and fecal (0.44%) corrinoid. Oral B(12) supplementation increased active B(12) at distal sites by >130-fold (cecal B(12) increased from 0.08 to 10.60 ng/mg, fecal B(12) increased from 0.06 to 7.81 ng/ml) and reduced microbe-derived fecal corrinoid analogues ([ADE]CN-Cba, [2Me-ADE]CN-Cba, [2MeS-ADE]CN-Cba). Oral B(12) had no effect on cecal SCFA. Microbial diversity was unaffected by this intervention, however a selective decrease in Bacteroides was observed with B(12) treatment. Lastly, no difference in markers of DSS-induced colitis were detected with B(12) treatment. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|